Literature DB >> 26411990

Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.

Naveen Pemmaraju1, Vikas Gupta2, Ruben Mesa3, Michael A Thompson4.   

Abstract

The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the field of hematology and oncology, a field which frequently experiences rapid shifts of information and novel, practice-changing discoveries. Among the many social media platforms available to cancer patients and providers, one platform in particular, Twitter, has become the focus for the creation of disease-specific communities, especially for those interested in, affected by, or those who perform research in the fields of rare cancers, which historically have had a dearth of reliable information available. This article will focus on the initiation and progress of one such Twitter hematology/oncology community, #mpnsm, which was originally created for the purpose of serving as a venue for improving the interaction among patients, providers, researchers, and organizations with interest in the myeloproliferative neoplasms (MPNs) and to further the availability of reliable up-to-date analysis; relevant expert commentary; and readily usable information for patients, providers, and other groups interested in this field.

Entities:  

Keywords:  Disease-specific hashtag; Myelofibrosis; Myeloproliferative neoplasm; Polycythemia vera; Social media; Twitter

Mesh:

Year:  2015        PMID: 26411990     DOI: 10.1007/s11899-015-0287-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  55 in total

1.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 3.  From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.

Authors:  Naveen Pemmaraju; Alison R Moliterno
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

4.  The social media revolution is changing the conference experience: analytics and trends from eight international meetings.

Authors:  Sarah E Wilkinson; Marnique Y Basto; Greta Perovic; Nathan Lawrentschuk; Declan G Murphy
Journal:  BJU Int       Date:  2015-01-26       Impact factor: 5.588

5.  Social media, text messaging, and email-preferences of asthma patients between 12 and 40 years old.

Authors:  Alan P Baptist; Michael Thompson; Karla Stoermer Grossman; Layla Mohammed; Annie Sy; Georgiana M Sanders
Journal:  J Asthma       Date:  2011-08-24       Impact factor: 2.515

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

8.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

9.  Social media and medical education: Exploring the potential of Twitter as a learning tool.

Authors:  Alireza Jalali; Jonathan Sherbino; Jason Frank; Stephanie Sutherland
Journal:  Int Rev Psychiatry       Date:  2015-03-13

10.  Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care.

Authors:  Carleen Hawn
Journal:  Health Aff (Millwood)       Date:  2009 Mar-Apr       Impact factor: 6.301

View more
  12 in total

1.  Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Jean-Jacques Kiladjian; Ruben Mesa; Michael A Thompson
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 2.  Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Authors:  Naveen Pemmaraju; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 3.  Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?

Authors:  Aaron T Gerds; Teresa Chan
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 4.  Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

5.  Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends.

Authors:  Naveen Pemmaraju; Michael A Thompson; Ruben A Mesa; Tejas Desai
Journal:  J Oncol Pract       Date:  2017-05-17       Impact factor: 3.840

Review 6.  Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine.

Authors:  Deanna J Attai; Patricia F Anderson; Michael J Fisch; David L Graham; Matthew S Katz; Jennifer Kesselheim; Merry Jennifer Markham; Nathan A Pennell; Mina S Sedrak; Michael A Thompson; Audun Utengen; Don S Dizon
Journal:  Semin Hematol       Date:  2017-08-12       Impact factor: 3.851

Review 7.  The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette.

Authors:  Naveen Pemmaraju; Ruben A Mesa; Navneet S Majhail; Michael A Thompson
Journal:  Semin Hematol       Date:  2017-08-24       Impact factor: 3.851

Review 8.  Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Jean-Jacques Kiladjian; Ruben Mesa; Michael A Thompson
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 9.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Authors:  Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Online and Social Media Resources for Patients with MDS.

Authors:  Nour Abuhadra; Aziz Nazha
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.